Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA finalizes residual solvent guidance

This article was originally published in The Tan Sheet

Executive Summary

Manufacturers of compendial drug products approved under a new drug application or in an abbreviated NDA may submit an analysis from a properly qualified component supplier to prove the required level of control of residual solvents in the finished product, an FDA final guidance says. The 1guidance notes FDA requires U.S.-marketed drug products with a U.S. Pharmacopoeia monograph to meet the requirements for control of residual solvents described in USP General Chapter 467. The guidance might still create a hurdle for approval of some generics, many of which were held up by FDA's initial interpretation of the revised USP standards last year. Under the final guidance, non-compendial products must follow an International Conference on Harmonization guideline - Q3C Impurities: Residual Solvents. Differences between the ICH requirement and USP's could be an issue for firms seeking to launch an ANDA product quickly
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS103589

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel